treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:

g lad

- (a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective adenoviral vector or an exogenous promoter; and wherein said cytokine is interleukin-2 or gamma-interferon; and
- (b) a pharmaceutically acceptable vehicle,
 wherein said pharmaceutical composition leads to regression of said
 tumor in at least 40% to 50% of patients.

18. (Twice Amended) The method according to Claim 15, wherein said nucleic acid sequence coding for said cytokine is under the control of said exogenous promoter.

33

- 23. (Once Amended) The method according to Claim 18, wherein said promoter is the promoter of the IE gene of cytomegalovirus.
- 24. (Once Amended) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition wherein said pharmaceutical composition comprises:
 - (a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective

adenoviral vector or an exogenous promoter; and wherein said cytokine is GM-CSF, and

(b) a pharmaceutically acceptable vehicle.

25. (Once Amended) The method according to Claim 24, wherein said adenoviral vector further comprises a nucleic acid sequence coding for an interleukin-2 under the control of a promoter present in said replication-defective adenoviral vector or an exogenous promoter and wherein said interleukin-2 under the control of said promoter present in said replication-defective adenoviral vector or said exogenous promoter is placed after said nucleic acid sequence coding for a cytokine in said adenoviral vector.

Please add the following new claim:

- 26. (New) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:
 - (a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of said adenovirus; and comprises a nucleic acid sequence coding for a cytokine, under the control of a promoter present in said replication-defective adenoviral vector selected from the group of an adenovirus late promoter and an adenovirus early promoter or an exogenous promoter selected from the group of a promoter contained in the long terminal repeat of a Rous Sarcoma Virus and a promoter of an IE gene of cytomegalovirus; and wherein said cytokine is interleukin-2 or gamma-interferon; and
 - a pharmaceutically acceptable vehicle,



wherein said pharmaceutical composition leads to regression and complete disappearance of said tumor in 40% to 50% of patients.